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LDL receptor enhancer evolution <p>Analysis of primate-specific evolution of the LDL receptor enhancer demonstrates a molecular mechanism by which ancestral mam- malian regulatory elements can evolve to perform new functions.</p>
Background:  Sequence changes in regulatory regions have often been invoked to explain
phenotypic divergence among species, but molecular examples of this have been difficult to obtain.
Results:  In this study we identified an anthropoid primate-specific sequence element that
contributed to the regulatory evolution of the low-density lipoprotein receptor. Using a
combination of close and distant species genomic sequence comparisons coupled with in vivo and
in vitro studies, we found that a functional cholesterol-sensing sequence motif arose and was fixed
within a pre-existing enhancer in the common ancestor of anthropoid primates.
Conclusion: Our study demonstrates one molecular mechanism by which ancestral mammalian
regulatory elements can evolve to perform new functions in the primate lineage leading to human.
Background
Since King and Wilson's provocative paper was published in
1975 [1], differences in gene regulatory sequences have been
predicted to be among the major sources of phenotypic evolu-
tion and divergence among animals. Consistent with this
hypothesis, cis-regulatory changes have been found to play an
important role in the evolution of morphologic features in
model organisms [2]. In contrast, evolution of physiology has
been linked to changes in protein coding sequences, when
studied in animal vision, digestive metabolism, and host
defense [3-7]. The contribution of regulatory sequence
changes to the evolution of physiologic differences, however,
is largely unexplored [8,9].
To examine the role of cis-regulatory changes in the emer-
gence of novel physiologic traits in primates, we investigated
the evolution of regulatory elements of the low-density lipo-
protein (LDL) receptor gene (LDLR), which is a key player in
maintaining lipid homeostasis. Cholesterol metabolism in
humans has diverged in a variety of ways from that of many
distant mammals such as rodents and dogs, with humans in
general being more susceptible to diet-induced hypercholes-
terolemia [10]. The pivotal role of LDLR in cholesterol metab-
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olism, coupled with its known expression differences among
mammals [11], makes it a prime candidate for investigating
primate-specific evolution of regulatory sequences. Here, we
present molecular data supporting the gain of a cholesterol-
sensing DNA motif in an ancestral mammalian LDLR regula-
tory element at a specific stage in primate evolution.
Results and discussion
Identification of primate-specific noncoding elements 
in the LDLR locus
To identify putative primate-specific LDLR  regulatory
sequences, we examined orthologous regions from a panel of
mammals closely and distantly related to human for the pres-
ence of evolutionarily conserved noncoding sequences using
Gumby, an algorithm that detects sequence blocks evolving
significantly more slowly than the local neutral rate (see
Materials and methods, below) [12-14]. Because humans and
nonhuman primates share many features of cholesterol
metabolism, we specifically scanned for elements that are
preferentially conserved in primates under the hypothesis
that primate-specific regulatory sequences contribute to the
distinctive biology of those species. We conducted pair-wise
sequence comparisons of the 83 kilobase (kb) genomic region
containing LDLR and its entire 5' and 3' intergenic regions
between human and each of a panel of distantly related spe-
cies consisting of the prosimian lemur, mouse, and dog. In
these comparisons we identified either the known promoter
sequence alone (Figure 1a and data not shown) or a limited
number of noncoding elements (Additional data file 1 and
Conservation profiles of the LDLR locus using close (primate) and distant (human-mouse) species comparisons Figure 1
Conservation profiles of the LDLR locus using close (primate) and distant (human-mouse) species comparisons. (a) Human-mouse and (b) multiple 
primate (human, baboon, colobus, dusky titi, marmoset, and owl monkey) conservation profiles were calculated using Gumby and visualized using 
RankVISTA (see Materials and methods) and displayed with the human sequence as reference. Only about 6 kilobases (kb) of the 5' intergenic region is 
shown because of incomplete primate sequence availability. The entire 3' intergenic region was included in the analysis. Vertical bars depict conserved 
exonic (light blue) and nonexonic (red) sequences, with height indicating statistical significance of sequence conservation (see Materials and methods). 
LDLR coding exons (dark blue) and untranslated regions (UTRs; magenta) are marked below the conservation plots. Arrows denote the two highest-
scoring primate-specific elements (PS1 and PS2). The inset shows the human-mouse VISTA plot for element PS2, with the vertical axis representing 
sequence identity calculated over a 100 base pair (bp) window.
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data not shown). The promoter region was the only noncod-
ing region consistently identified as being conserved in the
three pair-wise comparisons. In contrast, multiple sequence
comparisons between human and a set of five anthropoid pri-
mate species, chosen on the basis of their evolutionary rela-
tionship using the 'phylogenetic shadowing' strategy [15],
identified two human noncoding DNA elements, named PS
(primate specific) 1 and 2, which were found to be highly sig-
nificantly conserved (P approximately 10-5) in primates (Fig-
u r e  1 b ) .  H o w e v e r ,  t h e y  w e r e  u n d e t e c t e d  i n  c o m p a r i s o n s
involving human and each of the distant species (Figure 1 and
Additional data file 1).
To confirm independently the lack of significant conservation
of the PS1 and PS2 elements between human and distant
mammals, we also analyzed human-mouse alignment using a
sliding-window percentage identity conservation criterion.
We found that the human-mouse percentage identities across
PS1 and PS2 were below 50% (Figure 1 and data not shown).
This is close to the background percentage identity in aligned
intergenic DNA and is well below the threshold of 70% iden-
tity that is normally applied to the detection of conserved
functional sequences [16]. We further verified that the phast-
Cons program [17] detects no conserved sequences overlap-
ping PS1 and PS2 (data not shown). Although the phastCons
predictions, obtained from the UCSC Genome Browser, are in
general based on alignment of 17 mammalian and nonmam-
malian species, conservation scores in the LDLR locus reflect
only mammalian conservation because more distant genomes
exhibit very limited nonexonic alignment in this locus.
To assess quantitatively the conservation level of PS1 and PS2
between human and distant mammals, we identified the
orthologous aligned counterparts of the human PS1 and PS2
elements in lemur, mouse, and dog. Gumby analysis of con-
servation scores indicated that each of these nonanthropoid
primate sequences exhibited a level of similarity to the human
sequence consistent with unconstrained evolution at the neu-
tral rate (conservation P value; Table 1). Together, these anal-
yses strongly suggest a lack of significant sequence constraint
between the anthropoid primate and mammalian PS1 and
PS2 sequences.
The human LDLR PS2 element exhibits significantly 
greater enhancer activity than its mammalian 
orthologs
To explore the potential regulatory function of these two pri-
mate-specific conserved elements, we examined their ability
to drive reporter gene expression in both a transient transfec-
tion assay in human 293T cells and in an in vivo mouse liver
gene transfer assay [18]. Each human element plus approxi-
mately 200 base pairs (bp) of flanking sequence on either side
was cloned upstream of the human LDLR promoter [19] fused
to a luciferase reporter gene. Human element PS2, but not
PS1, consistently increased luciferase expression approxi-
mately fivefold relative to the human promoter alone in both
the in vitro and in vivo assays (Figure 2). The human element
PS2 also increased luciferase expression when cloned
upstream of the generic SV40 promoter, albeit to a lesser
extent (twofold; Additional data file 3). Enhancer activity of
this element was further confirmed by the finding that
genomic region corresponding to PS2, but not PS1, is a DNa-
seI hypersensitive site in human liver cells (Additional data
file 2 and data not shown).
To explore the regulatory function, if any, of mammalian
sequences orthologous to human PS2, we cloned the PS2-
aligned sequences from lemur, mouse, and dog into the luci-
ferase reporter vector described above and compared their
activities with that of the human sequence. Despite the lack of
statistically significant sequence constraint between the
human enhancer and its lemur, mouse, and dog orthologs,
the latter three sequences exhibited enhancer activity both in
vitro and in vivo (Figure 2). The human regulatory element,
Table 1
PS2 enhancer functional divergence correlates with sequence constraint
Sequence analysis Functional test
Species compared Conservation P value Species assayed Relative enhancer strength
PS1 PS2 PS1 PS2
Human/5 primates 4.8 × 10-5 10-5 Human 0.9 5.1
Human/lemur ~1 0.76 Lemur ND 2.6
Human/mouse ~1 ~0.99 Mouse ND 1.5
Human/dog 0.28 0.45 Dog ND 2.6
Conservation P values are calculated using Gumby [12] under the null hypothesis of evolution at the neutral (background) rate. Low P values indicate 
that the null model of neutrality should be rejected, with the lowest P values identify the most significantly conserved sequences. The sequences 
analyzed for human-mammal conservation or enhancer activity correspond to the Gumby predicted conserved sequence and approximately 200 
base pairs of flanking sequence on either side (see Materials and methods). Enhancer strength is shown as fold increase over promoter alone in 
luciferase assays in 293T cells. ND, not done.R68.4 Genome Biology 2006,     Volume 7, Issue 8, Article R68       Wang et al. http://genomebiology.com/2006/7/8/R68
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however, consistently exhibited stronger enhancer activity in
both assays, driving twofold greater expression than lemur or
dog PS2 and fourfold greater expression than mouse (Figure
2a). This observation, coupled with the evidence of negative
selection acting on the primate enhancer and the lack of sig-
nificant sequence constraint between the anthropoid primate
and mammalian PS2 sequences (conservation P value; Table
1), suggests that the stronger enhancer activity in human is a
gain of function in the anthropoid primate lineage with a
potentially important adaptive role in these species.
An anthropoid-primate specific sterol regulatory 
element contributes to distinct human PS2 enhancer 
activity
To identify the molecular basis of the primate-specific activity
of PS2, we computationally dissected the 860 bp human PS2
enhancer (see Materials and methods, below) and found a
sterol regulatory element (SRE). This is a binding site specif-
ically recognized by the cholesterol sensing proteins SREBPs
(sterol regulatory element binding proteins), which are
known to play a key role in the regulation of LDLR [20,21].
Phylogenetic analysis of the orthologous PS2 sequences from
three distant mammals (mouse, rat, and dog), three prosimi-
ans (lemur, mouse lemur and galago), and nine anthropoid
primates covering all major lineages including hominoids,
and old-world and new-world monkeys revealed the presence
of the SRE exclusively in anthropoid primates (Figure 3). This
phylogenetic distribution of the SRE in mammals can most
parsimoniously be explained by the appearance of the SRE in
the ancestor of anthropoid primates after its divergence from
prosimians (Figure 3).
The functional role of the binding motif identified by compu-
tational analysis was explored by site-specific mutagenesis. A
4 bp substitution was introduced into the SRE, which was
expected to inactivate the site completely based on a previ-
ously reported mutagenesis study [22]. The 4 bp substitution
in the SRE decreased human enhancer activity in the human
cell culture assay and the in vivo mouse liver DNA transfer
assay to a level comparable with that in lemur, mouse, and
dog enhancers; these species lack a computationally pre-
dicted SRE (Figure 2). The functionality of the SRE, found
exclusively in anthropoid primates, suggests that this element
is likely to contribute to the stronger activity found in these
species. We also identified within the 860 bp enhancer a 21 bp
subregion that exhibits strong conservation across mamma-
lian species including lemur, mouse lemur, galago, mouse
and dog, and that contains predicted binding sites for tran-
scription factors activating enhancer binding protein (AP)-4
and AP-1. Deletion of the conserved 21 bp sequence from
either human or dog PS2 resulted in a significant reduction in
enhancer activity (data not shown), suggesting that the evolu-
tionarily conserved AP-4 and AP-1 sites are important for the
core enhancer activity shared among mammals. It is worth
noting that such short blocks of genuinely constrained
sequence are not easily distinguishable from the numerous
Human LDLR PS2 enhancer exhibits significantly higher activity than  orthologous lemur, mouse, and dog enhancers Figure 2
Human LDLR PS2 enhancer exhibits significantly higher activity than 
orthologous lemur, mouse, and dog enhancers. Luciferase assay analysis of 
(a) transient transfections into human 293T cells and (b) plasmid DNA 
transfer into mouse liver. The luciferase reporter constructs tested are 
either the LDLR promoter alone (promoter) or the promoter in 
combination with the LDLR PS2 enhancer from one of the indicated 
species. Error bars indicate standard deviation. 'SRE mutant' refers to the 
mutagenized human sterol regulatory element (SRE) with four point 
substitutions relative to the wild-type (WT) SRE (Figure 4a). Luciferase 
activity is reported in arbitrary units. Each triangle in panel b represents 
luciferase activity in an individual mouse. Red bars denote the median 
activity of each construct.
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'coincidentally conserved' sequence fragments that are likely
to occur in large genomic regions as a consequence of sto-
chastic variation in the incidence of neutral mutations. Incor-
poration of additional information, namely the binding
specificities of transcription factors, was required to classify
this 21 bp fragment as a functional candidate. Thus, conserva-
tion of this short subsequence in multiple mammals does not
detract from the fact that the enhancer sequence is signifi-
cantly conserved only in anthropoid primates, as described
above.
Because SREBP-2, the major regulator of LDLR [20,21], spe-
cifically binds to the SRE [11], we examined the responsive-
ness of the human, lemur, mouse, and dog orthologous PS2
enhancers to this transcription factor. Co-transfection of the
reporter gene driven by PS2 and the human LDLR promoter
with a construct expressing the mature form of SREBP-2 indi-
cated that the human enhancer was strongly activated by the
exogenous SREBP-2, to a level fivefold higher than that of the
human LDLR promoter alone, which is known to be SREBP
responsive as well [23]. The lemur, mouse, and dog enhancers
were activated to a significantly lesser extent, which is con-
sistent with their much lower SRE prediction score and with
their lack of additional consensus SRE motifs within the PS2
element (Figure 3, Figure 4a, and data not shown). To deter-
mine whether the observed differential SREBP-2 response
among tested mammalian PS2 enhancers was directly medi-
ated by the predicted SRE, we inactivated or restored the con-
sensus SRE by site-specific mutagenesis at the orthologous
positions of the human and dog PS2 element, respectively.
Substituting four bases in the human SRE motif, which
reduced the motif matrix score from 1 to 0.35 (see Materials
and methods, below), resulted in a reduction in SREBP-2
enhancer response to a level comparable to that of the lemur,
mouse, and dog enhancers. These results indicate that the
anthropoid-specific SRE mediates the activation of the PS2
enhancer by SREBP-2 and contributes to the strong enhancer
activity characterizing human and other anthropoid pri-
mates. Furthermore, substituting three bases in the dog SRE,
so as to increase the SRE motif score from 0.47 to 1 (repre-
senting a perfect SRE), led to a significant increase in the dog
enhancer response to SREBP-2, although only to half the level
of the human PS2 enhancer (Figure 4b). This suggests that
the anthropoid primate-specific SRE is part of a combinato-
rial mechanism [24], including possible additional substitu-
tions in the core enhancer element that contribute to the
stronger human PS2 enhancer activity.
The role of SREBP-2 in regulating the human PS2 enhancer
was further explored in its native chromosomal context in
HepG2 cells, which actively express SREBP-2 and are a well
defined system for studying LDLR regulation [25-27]. Our
analysis showed that the PS2 sequence is a DNaseI hypersen-
sitive site in HepG2 cells (Additional data file 2), suggesting
that the corresponding DNA element is involved in transcrip-
tional regulation of the endogenous gene. Using the ChIP
(chromatin immunoprecipitation )  a s s a y ,  w e  w e r e  a b l e  t o
show that fractionation of chromatin with an anti-SREBP-2
antibody specifically enriched for endogenous PS2 and LDLR
promoter DNA relative to control region (Figure 5); the latter
has previously been shown to be bound by SREBP-2 [28].
Together, the DNAseI hypersensitivity and ChIP assays pro-
vide strong evidence that SREBP-2 binds in the vicinity of the
human PS2 enhancer in its native genomic locus. Regulation
of the enhancer by SREBP-2 also suggests that the PS2 ele-
ment plays a role in the activation of its upstream gene LDLR
rather than the downstream gene Spbc24, which encodes a
component of the kinetochore Ndc80 protein complex [29]. It
was recently noted, based on genome-wide analysis of gene
expression, that SREBP targets are largely restricted to lipid
metabolism genes, including LDLR [20]. No connection was
found between SREBP and kinetochore structural genes such
as Spbc24.
Conclusion
We have shown phylogenetic and molecular data supporting
the evolution of differential gene expression of LDLR  in
mammals. Transcriptional control of LDLR is mainly effected
through the intracellular cholesterol sensor SREBP-2. The
latter was previously shown to mediate the increased tran-
scription of LDLR  in response to low cholesterol levels
through an SRE in the LDLR promoter [23,30], which is con-
served in all mammals examined. The additional SRE found
in the PS2 enhancer in primates may lead to differential
response to SREBP-2 among mammals. Although the contri-
Phylogenetic analysis of the SRE Figure 3
Phylogenetic analysis of the SRE. The human sterol regulatory element 
(SRE) motif and its orthologs were scored for transcription factor binding 
affinity, with low motif scores indicating low predicted affinity to SRE 
binding protein (SREBP; see Materials and methods). Because the SRE is 
present in all the analyzed anthropoid primates (indicated by the red 
branches in the tree) and absent from the prosimians, rodents, and dog, 
emergence in the lineage leading to anthropoid primates is the most 
parsimonious explanation.
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bution of the PS2 enhancer to the in vivo regulation of LDLR
remains to be elucidated, these results suggest that species-
specific regulation of LDLR  is expected in conditions that
result in decreased intracellular cholesterol levels, such as
reduced availability of dietary cholesterol, and has implica-
tions for the study of LDLR response to cholesterol-lowering
drugs in animal models.
Although the human LDLR coding sequence and promoter
are well conserved in all sequenced mammals (Figure 1 and
Additional data file 1), our data support the modification of
the expression characteristics of this gene through the pri-
mate-specific evolution of a distal regulatory element. We
have shown the emergence and fixation of a SRE in the com-
mon ancestor of anthropoid primates, which modifies the
expression driven by a pre-existing mammalian enhancer
shared by all tested mammals. This demonstrates one mech-
anism by which mammalian regulatory elements can evolve
to perform new functions. Given the vital importance of
LDLR in energy storage, the appearance of a new cholesterol
sensing element in the LDLR enhancer might have played a
role in the evolution of new physiologic features, because the
ancestor of anthropoid primates adapted to different meta-
bolic requirements and diets.
Materials and methods
Plasmid constructs
The human LDLR promoter was cloned in the proper orien-
tation upstream of the luciferase cDNA in the pGL3Basic con-
struct (Promega, Madison, WI, USA). The human PS1
element and the PS2 elements from human, lemur, mouse,
and dog LDLR loci were polymerase chain reaction (PCR)
cloned into poly-linker sites in the (-) orientation upstream of
the promoter. The cloned human PS1 element corresponds to
the Gumby predicted conserved sequence and approximately
200 bp of flanking sequence on either side (hg18,
chr19:11067913-11068639). To clone the human PS2 ele-
ment, the region containing human PS2 was PCR cloned into
pGL3Basic (see Additional data file 4 for primer sequences),
and digested with SpeI and NheI to only include the Gumby
predicted conserved sequence and approximately 200 bp of
f l a n k i n g  s e q u e n c e  o n  e i t h e r  s i d e  ( h g 1 8 ,  c h r 1 9 : 1 1 1 1 0 3 3 3 -
11111194). Site-specific point mutations and deletions were
introduced into human and dog PS2 elements using Quik-
ChangeII site-directed mutagenesis kit (Stratagene, La Jolla,
CA, USA), in accordance with the manufacturer's protocol
and were confirmed by sequencing. The expression construct
for human mature form of SREBP-2 (pcDNA.2FLAG SREBP-
2) was kindly provided by Dr Timothy F Osborne (UC Irvine).
The human LDLR promoter (hg18, chr19:11060880-
Relation between SRE motif score and response of PS2 enhancer to SREBP-2 Figure 4
Relation between SRE motif score and response of PS2 enhancer to SREBP-2. (a) Alignment of sequences from indicated species at positions orthologous 
to human PS2 sterol regulatory element (SRE). 'Human mutant' refers to the mutated human SRE with four point substitutions relative to the human wild-
type. 'Dog mutant' refers to the consensus SRE introduced into dog PS2 by means of three point substitutions. (b) Luciferase assay analysis of reporter 
construct and the SRE binding protein (SREBP)-2 expression vector cotransfection into 293T cells. The LDLR PS2 element from each of the indicated 
species was tested in combination with the LDLR promoter. The Y-axis denotes SRE motif score (likeness to known SRE motifs; see Materials and 
methods). Response of the PS2 element to SREBP-2 is shown as the increase in luciferase expression level (arbitrary units) on activation by 3 ng SREBP-2 
expression vector. Expression level increase for LDLR promoter alone is indicated by the dotted line. Error bars indicate standard deviation.
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11061099) was PCR amplified (see Additional data file 4 for
primers used).
Transient transfection reporter assay
Cells of human embryonic kidney cell line 293T (ATCC CRL-
11268) were grown at 37°C and 5% carbon dioxide CO2 in
Dulbecco's modified Eagle's medium (ATCC), supplemented
with 10% fetal bovine serum (Hyclone, Logan, UT, USA), l-
glutamine, and penicillin-streptomycin. Cells with a passage
number below 15 were used. The cells were grown in 12-well
plates (4 × 104  cells/well) and transfected using Fugene
(Roche Molecular Biochemicals, Indianapolis, IN, USA), in
accordance with the manufacturer's protocol. Briefly, 100 ng
of each assayed plasmid and 10 ng pCMVβ (BD Biosciences,
Franklin Lakes, NJ, USA) were mixed with 1.5 µl Fugene and
added to each well. Following 42-48 hours of incubation, cells
were harvested and lysed. Activity of luciferase and β-galac-
tosidase was measured using the Luciferase Assay System
(Promega) and the Galacto-Light Plus (Applied Biosystems,
Foster City, CA, USA), respectively. Luciferase activity for
each sample was normalized to the β-galactosidase assay con-
trol. For co-transfection experiments, 100 ng of the lulcif-
erase reporter gene construct, 3 ng of SREBP-2 expression
vector, and 10 ng of pCMVβ were used. Transfections were
carried out in duplicate. All experiments are representative of
at least three independent transfections.
Tail vein plasmid DNA transfer assays
Tail vein injection was performed as described by Herweijer
and Wolff [18], following the TransIT® In Vivo Gene Delivery
System (Mirus Corporation, Madison, WI, USA) protocol. Six
to nine FVB male mice (Charles River Laboratory, Wilming-
ton, MA, USA) at age 7-8 weeks were used for each reporter
gene construct. Ten micrograms of each reporter construct,
along with 2 µg of pCMVβ (BD Biosciences) to correct for
delivery efficiency, were injected into each mouse. The entire
content of the syringe was delivered in 3-5 s. Animals were
killed 24 hours later, livers extracted, measured to correct for
size, homogenized, and centrifuged for 15 min at 4°C, 14,000
rpm. Activities of luciferase and β-galactosidase were meas-
ured as described above. All P values are from the two-sample
Wilcoxon rank-sum (Mann-Whitney) test using STATA
(STATA Corporation, College Station, TX, USA). All experi-
mental results are representative of two independent plasmid
DNA transfer assays.
Chromatin immunoprecipitation
HepG2 cells (ATCC HB-8065) were cultured in DMSF
(defined medium serum free) medium for 24 hours for induc-
tion of endogenous SREBPs [31]. Chromatin immunoprecip-
itaion assays were performed as described previously [32].
Cross-linked chromatin was immunoprecipitated with a spe-
cific SREBP-2 antibody (Santa Cruz sc-8151) [8] or IgG con-
trol.
Sources of sequence data
Draft sequences of baboon, colobus, dusky titi, marmoset,
owl monkey, lemur, and galago bacterial artificial chromo-
somes (BACs) were determined by sequencing ends of 3 kb
subclones to 8- to 10-fold coverage using BigDye terminators
(Applied Biosystems) and assembling reads into contigs with
the Phred-Phrap-Consed suite, as described previously [33].
All BAC sequences were submitted to GenBank with the fol-
lowing species and accession numbers: baboon (Papio
hamadryas), AC140974; colobus (Colobus guereza),
AC150433; marmoset (Callithrix jacchus), AC145530; dusky
titi (Callicebus moloch), AC144655; owl monkey (Aotus
hybrid), AC171393; squirrel monkey (Saimiri boliviensis
boliviensis), AC146467; lemur (lemur catta), AC118569;
mouse lemur (microcebus murinus), AC175656; and galago
(otolemur garnetti), AC175655). Human, chimpanzee, rhe-
sus, mouse, rat, and dog sequences were downloaded from
the UCSC Genome Bioinformatics website [34].
Analysis of sequence conservation
We aligned the human LDLR  locus (chr19:11,055,219-
11,117,169; NCBI Build 35) to its orthologs in baboon, colobus,
dusky titi, marmoset, owl monkey, lemur, mouse, and dog
using MLAGAN [35]. Because incomplete primate sequence
Anti-SREBP-2 antibody specifically enriches human PS2 DNA sequences in  HepG2 cells in a ChIP assay Figure 5
Anti-SREBP-2 antibody specifically enriches human PS2 DNA sequences in 
HepG2 cells in a ChIP assay. DNA precipitates were measured by real-
time polymerase chain reaction using primers spanning the indicated 
regions. Control region (control) corresponds to the first coding exon of 
the neighboring gene SPBC24, which is approximately 7.5 kilobases away 
from the PS2 sequence. The results are presented as fold increase in the 
enrichment of precipitated DNA by anti-SREBP-2 (anti-sterol regulatory 
element binding protein-2) antibody over nonspecific IgG. Graphical 
representations of the mean ± standard error from three independent 
experiments are shown.
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availability, we included only about 6 kb of the 5' intergenic
region in the analysis. Aligned sequences were scanned for
statistically significant evolutionarily conserved regions using
Gumby [12-14]. Gumby goes through the following three-step
process to identify statistically significant conservation in the
global alignment input. First, noncoding regions in the align-
ment are used to estimate the local neutral mismatch rates
among all pairs of aligned sequences. The rates are used to
derive a log-likelihood scoring scheme for slow versus neutral
evolution, in which the slow rate is set to some fraction (in
this case, half) of the neutral rate. Second, each alignment
position is then assigned a conservation score using a phylo-
genetically weighted sum-of-pairs scheme. Third, conserved
regions of any length are identified as alignment blocks with
a high cumulative conservation score and assigned P values
using Karlin-Altschul statistics [36]. We set a threshold P
value of 0.1 in a baseline human sequence length of 10 kb.
Conserved regions identified by Gumby were visualized using
RankVISTA. In addition, human-mouse sequence conserva-
tion was analyzed using the VISTA web server [37,38], with
the standard criterion of 70% sequence identity in window of
size 100 bp.
Binding site prediction
We scanned the aligned enhancer sequences for predicted
transcription factor binding sites using DiAlign TF [39].
Anthropoid primate (human, baboon, colobus, dusky titi,
marmoset, and owl monkey) sequences were assessed for the
presence of sites conserved across all six species that were
predicted to bind one of the following liver-expressed tran-
scription factors: C/EBP (CCAAT/enhancer-binding pro-
tein), LXR (liver X receptor), FXR (farnesoid X receptor),
COUP-TF (Chicken Ovalbumin Upstream Promoter Tran-
scription Factor), peroxisome proliferator-activated receptor
(PPAR), HNF1 (hepatocyte nuclear factor 1), HNF3, HNF4,
and SREBP. Binding sites common to primates and mammals
were predicted on the basis of conservation of any vertebrate
transcription factor motif in at least eight of the 10 analyzed
species (six anthropoid primates, lemur, mouse, rat, and
dog). Motif scores of the SREs or SRE orthologs of individual
species were calculated using rVISTA [40] and normalized so
that the maximum achievable score is 1.0, and the expected
score of a random nucleotide sequence with the local GC con-
tent is zero. The score distribution of functional SREs was cal-
culated from the binding profile of SREBP [41], assuming that
nucleotide frequencies at each position in the motif are inde-
pendent. We retrospectively augmented the species set with
SRE orthologs from chimpanzee, rhesus, squirrel monkey,
mouse lemur and galago, based on pair-wise alignments of
those species to human.
Additional data files
The following additional data are available with the online
version of this paper: A figure showing the conservation pro-
files of the LDLR locus using (A) human-dog and (B) human-
lemur sequence comparisons (Additional data file 1); a figure
showing the DNaseI hypersensitive site mapping around the
LDLR PS2 region in human liver cell line HepG2 (Additional
data file 2); a figure showing that human LDLR PS2 enhancer
activity is independent of the LDLR  promoter (Additional
data file 3); a table listing the primers used in the cloning of
human  LDLR  promoter and PS2 elements from indicated
species (Additional data file 4); and a table listing the primers
used in ChIP assay (Additional data file 5).
Additional data file 1 Conservation profiles of the LDLR locus A figure showing the conservation profiles of the LDLR locus using  (A) human-dog and (B) human-lemur sequence comparisons. Click here for file Additional data file 2 DNaseI hypersensitive site mapping A figure showing the DNaseI hypersensitive site mapping around  the LDLR PS2 region in human liver cell line HepG2. Click here for file Additional data file 3 Human LDLR PS2 enhancer activity A figure showing that human LDLR PS2 enhancer activity is inde- pendent of the LDLR promoter. Click here for file Additional data file 4 Primers used in the cloning of human LDLR promoter and PS2 ele- ments from indicated species A table listing the primers used in the cloning of human LDLR pro- moter and PS2 elements from indicated species. Click here for file Additional data file 5 Primers used in ChIP assay A table listing the primers used in ChIP assay. Click here for file
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